

Bastien Joubert

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9398518/publications.pdf>

Version: 2024-02-01

66
papers

2,449
citations

218381

26
h-index

214527

47
g-index

73
all docs

73
docs citations

73
times ranked

1799
citing authors

#	ARTICLE	IF	CITATIONS
1	Core cerebrospinal fluid biomarker profile in anti-LGI1 encephalitis. <i>Journal of Neurology</i> , 2022, 269, 377-388.	1.8	10
2	How to diagnose and manage neurological toxicities of immune checkpoint inhibitors: an update. <i>Journal of Neurology</i> , 2022, 269, 1701-1714.	1.8	14
3	Glial Fibrillary Acidic Protein Autoimmunity. <i>Neurology</i> , 2022, 98, .	1.5	61
4	Novelties in Autoimmune and Paraneoplastic Cerebellar Ataxias: Twenty Years of Progresses. <i>Cerebellum</i> , 2022, 21, 573-591.	1.4	17
5	Prognostic Factors and Treatment Efficacy in Spinal Cord Sarcoidosis. <i>Neurology</i> , 2022, 98, .	1.5	6
6	Human CASPR2 Antibodies Reversibly Alter Memory and the CASPR2 Protein Complex. <i>Annals of Neurology</i> , 2022, 91, 801-813.	2.8	17
7	Cranial Nerve Disorders Associated With Immune Checkpoint Inhibitors. <i>Neurology</i> , 2021, 96, e866-e875.	1.5	44
8	Placental transfer of NMDAR antibodies causes reversible alterations in mice. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	3.1	17
9	Familial autoimmunity in neurological patients with GAD65 antibodies: an interview-based study. <i>Journal of Neurology</i> , 2021, 268, 2515-2522.	1.8	4
10	Recurrent seizures of autoimmune origin: emerging phenotypes. <i>Journal of Neurology</i> , 2021, 268, 3000-3010.	1.8	2
11	Clinical and Prognostic Value of Immunogenetic Characteristics in Anti-LGI1 Encephalitis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	3.1	43
12	Distinctive clinical presentation and pathogenic specificities of anti-AK5 encephalitis. <i>Brain</i> , 2021, 144, 2709-2721.	3.7	23
13	Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	3.1	313
14	Argonaute Autoantibodies as Biomarkers in Autoimmune Neurologic Diseases. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	3.1	15
15	Role of LGI1 protein in synaptic transmission: From physiology to pathology. <i>Neurobiology of Disease</i> , 2021, 160, 105537.	2.1	15
16	Anti-CASPR2 clinical phenotypes correlate with HLA and immunological features. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 1076-1084.	0.9	53
17	Epidemiology of paraneoplastic neurologic syndromes and autoimmune encephalitides in France. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	3.1	74
18	Primary DQ effect in the association between HLA and neurological syndromes with anti-GAD65 antibodies. <i>Journal of Neurology</i> , 2020, 267, 1906-1911.	1.8	18

#	ARTICLE	IF	CITATIONS
19	Transient Neurological Symptoms Preceding Cerebellar Ataxia with Glutamic Acid Decarboxylase Antibodies. <i>Cerebellum</i> , 2020, 19, 715-721.	1.4	9
20	Pathophysiology of paraneoplastic and autoimmune encephalitis: genes, infections, and checkpoint inhibitors. <i>Therapeutic Advances in Neurological Disorders</i> , 2020, 13, 175628642093279.	1.5	57
21	Avoiding New Biopsies by Identification of IDH1 and TERT Promoter Mutation in Nondiagnostic Biopsies From Glioma Patients. <i>Neurosurgery</i> , 2020, 87, E513-E519.	0.6	10
22	Pregnancy outcomes in anti-NMDA receptor encephalitis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	3.1	30
23	Complications neurologiques des immunothérapies anti-cancéreuses: une pathologie émergente. <i>Pratique Neurologique - FMC</i> , 2020, 11, 60-68.	0.1	0
24	Clinical spectrum and diagnostic pitfalls of neurologic syndromes with Ri antibodies. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	3.1	58
25	Long-term outcomes in temporal lobe epilepsy with glutamate decarboxylase antibodies. <i>Journal of Neurology</i> , 2020, 267, 2083-2089.	1.8	28
26	Central nervous system complications associated with immune checkpoint inhibitors. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 772-778.	0.9	92
27	Paraneoplastic cerebellar ataxia and antibodies to metabotropic glutamate receptor 2. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	3.1	39
28	Diagnostic yield of commercial immunodots to diagnose paraneoplastic neurologic syndromes. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	3.1	74
29	Increased frequency of anti-Ma2 encephalitis associated with immune checkpoint inhibitors. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019, 6, .	3.1	129
30	The role of infections in autoimmune encephalitides. <i>Revue Neurologique</i> , 2019, 175, 420-426.	0.6	28
31	Seizure specificities in patients with antibody-mediated autoimmune encephalitis. <i>Epilepsia</i> , 2019, 60, 1508-1525.	2.6	57
32	JS1.2 Increased frequency of paraneoplastic encephalitis with anti-Ma2 antibodies in the cancer immunotherapy era. <i>Neuro-Oncology</i> , 2019, 21, iii4-iii5.	0.6	0
33	Unilateral clinical manifestations in LGI1-antibody encephalitis. <i>Revue Neurologique</i> , 2019, 175, 481-483.	0.6	2
34	P14.88 Comparison of SNaPshot PCR and digital droplet PCR for the identification of TERT promoter in non-diagnostic biopsies from glioma patients. <i>Neuro-Oncology</i> , 2019, 21, iii88-iii88.	0.6	0
35	Nonparaneoplastic autoimmune cerebellar ataxias. <i>Current Opinion in Neurology</i> , 2019, 32, 484-492.	1.8	23
36	Neuropathic pain, dysautonomia, and nerve hyperexcitability: Expanding the spectrum of LGI1 autoimmunity. <i>Clinical Neurophysiology</i> , 2019, 130, 248-250.	0.7	2

#	ARTICLE	IF	CITATIONS
37	Radiological Characteristics and Natural History of Adult IDH-Wildtype Astrocytomas with TERT Promoter Mutations. <i>Neurosurgery</i> , 2019, 85, E448-E456.	0.6	20
38	Isolated seizures are a common early feature of paraneoplastic anti-GABAB receptor encephalitis. <i>Journal of Neurology</i> , 2019, 266, 195-206.	1.8	58
39	TRIM9 and TRIM67 Are New Targets in Paraneoplastic Cerebellar Degeneration. <i>Cerebellum</i> , 2019, 18, 245-254.	1.4	44
40	Balint syndrome in anti-NMDA receptor encephalitis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019, 6, e532.	3.1	2
41	Motor neuron involvement in anti-Ma2-associated paraneoplastic neurological syndrome. <i>Journal of Neurology</i> , 2019, 266, 398-410.	1.8	31
42	GAD65 Ab encephalitis and subtle focal status epilepticus. <i>Epileptic Disorders</i> , 2019, 21, 437-442.	0.7	4
43	Nivolumab-induced myositis: A case report and a literature review. <i>Journal of the Neurological Sciences</i> , 2018, 387, 51-53.	0.3	31
44	Glioblastoma as differential diagnosis of autoimmune encephalitis. <i>Journal of Neurology</i> , 2018, 265, 669-677.	1.8	30
45	Multiplex family with GAD65-Abs neurologic syndromes. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2018, 5, e416.	3.1	16
46	Rechallenge with bevacizumab in patients with glioblastoma progressing off therapy. <i>Journal of Neuro-Oncology</i> , 2018, 138, 141-145.	1.4	6
47	Initial clinical presentation of young children with N-methyl-d-aspartate receptor encephalitis. <i>European Journal of Paediatric Neurology</i> , 2018, 22, 404-411.	0.7	26
48	Muscular disorder related to immune checkpoint inhibitors: forewarned is forearmed. <i>Neuro-Oncology</i> , 2018, 20, 861-862.	0.6	3
49	NIMG-43. RADIOLOGICAL CHARACTERISTICS AND NATURAL HISTORY OF ADULT IDH WILD-TYPE ASTROCYTOMAS WITH TERT PROMOTER MUTATIONS. <i>Neuro-Oncology</i> , 2018, 20, vi185-vi186.	0.6	0
50	PATH-36. IDH AND TERT PROMOTER MUTATIONS IN NON-DIAGNOSTIC BIOPSIES FROM GLIOMA PATIENTS. <i>Neuro-Oncology</i> , 2018, 20, vi166-vi166.	0.6	0
51	Movement disorders in autoimmune encephalitis and paraneoplastic neurological syndromes. <i>Revue Neurologique</i> , 2018, 174, 597-607.	0.6	14
52	Contactin-associated protein-like 2, a protein of the neurexin family involved in several human diseases. <i>European Journal of Neuroscience</i> , 2018, 48, 1906-1923.	1.2	56
53	Immune-mediated ataxias. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2018, 155, 313-332.	1.0	38
54	Characteristics in limbic encephalitis with anti-adenylate kinase 5 autoantibodies. <i>Neurology</i> , 2017, 88, 514-524.	1.5	49

#	ARTICLE	IF	CITATIONS
55	Netrin-1 receptor antibodies in thymoma-associated neuromyotonia with myasthenia gravis. <i>Neurology</i> , 2017, 88, 1235-1242.	1.5	28
56	Association of Prognostic Factors and Immunosuppressive Treatment With Long-term Outcomes in Neurosarcoidosis. <i>JAMA Neurology</i> , 2017, 74, 1336.	4.5	76
57	Anaplastic gliomas in adults: an update. <i>Current Opinion in Oncology</i> , 2017, 29, 434-442.	1.1	10
58	First case report of Nivolumab-induced dermatomyositis. <i>Neuromuscular Disorders</i> , 2017, 27, S152.	0.3	1
59	Autoimmune episodic ataxia in patients with anti-CASPR2 antibody-associated encephalitis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2017, 4, e371.	3.1	64
60	Characterization of a Subtype of Autoimmune Encephalitis With Anti-Contactin-Associated Protein-like 2 Antibodies in the Cerebrospinal Fluid, Prominent Limbic Symptoms, and Seizures. <i>JAMA Neurology</i> , 2016, 73, 1115.	4.5	155
61	Computer-aided Therapeutics in Treating Autoimmune Encephalitis—Reply. <i>JAMA Neurology</i> , 2016, 73, 128.	4.5	0
62	Consensus Paper: Neuroimmune Mechanisms of Cerebellar Ataxias. <i>Cerebellum</i> , 2016, 15, 213-232.	1.4	142
63	Autoimmune channelopathies in paraneoplastic neurological syndromes. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2015, 1848, 2665-2676.	1.4	25
64	Clinical Spectrum of Encephalitis Associated With Antibodies Against the α -Amino-3-Hydroxy-5-Methyl-4-Isoxazolepropionic Acid Receptor. <i>JAMA Neurology</i> , 2015, 72, 1163.	4.5	123
65	Brain pseudo-tumoral inflammatory lesion associated with chronic myelomonocytic leukemia. <i>Journal of Neuro-Oncology</i> , 2013, 113, 149-150.	1.4	4
66	Long-term evolution and prognostic factors of epilepsy in limbic encephalitis with LGI1 antibodies. <i>Journal of Neurology</i> , 0, , .	1.8	8